Genedrive PLC (LON:GDR) chief executive David Budd hailed as 'excellent' the results from an Indian study that showed the group's hepatitis-C (HCV) testing kit was able to determine who did and didn’t have the disease with 100% accuracy.
Overall, the data demonstrated that the rapid point-of-care device was suitable for use in a country where infections estimated at between six and 12 million, the company added.
"These excellent clinical results for our HCV assay further validate the applicability of the test for a decentralised setting,” explained Budd. “India is a key target market for our assay and we are excited about the commercial prospects in the region."
The work was carried out by Dr Ekta Gupta at the Institute of Liver and Biliary Sciences, New Delhi, who assessed 320 people (150 of whom were HCV-positive) using the portable diagnostic device.
Accuracy was measured by comparing the Genedrive results with those from the lab-based Abbott m2000 platform.
The assessment carried out across a demographic range using different genotypes, “to ensure suitability for the introduction of the product to the Indian population”.
For more information click here.